Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
32.96
+0.06 (0.18%)
Mar 14, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Revenue
In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M, down -10.48%. Ionis Pharmaceuticals had revenue of $226.58M in the quarter ending December 31, 2024, a decrease of -30.18%.
Revenue (ttm)
$705.14M
Revenue Growth
-10.48%
P/S Ratio
6.99
Revenue / Employee
$659,624
Employees
1,069
Market Cap
5.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
IONS News
- 3 days ago - Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera - Business Wire
- 3 days ago - Ionis and Ono announce global license agreement for sapablursen in polycythemia vera - Business Wire
- 5 days ago - WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy - Business Wire
- 17 days ago - Ionis to present at upcoming investor conferences - Business Wire
- 22 days ago - New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - Business Wire
- 23 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval - Seeking Alpha
- 23 days ago - Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - Benzinga